Publications

Original Publications in Peer Reviewed Journals:

  1. Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil and Radiotherapy Followed by Resection. Am J Clin Oncol, accepted for publication.
  2. Boland PM, Fakih M. The emerging role of neoadjuvant chemotherapy for rectal cancer. J Gastrointest Oncol, 2014 Oct;5(5):362-73.
  3. Perkins J, Boland P, Cohen SJ, Olszanski AJ, Zhou Y, Engstrom P, Astsaturov I. Successful Imatinib Therapy for Neuroendocrine Carcinoma With Activating KIT Mutation: A Case Study. J Natl Compr Canc Netw. 2014 Jun;12(6):847-52.
  4. Boland PM, Burtness B. Esophageal Carcinoma: Are Modern Targeted Therapies Shaking the Rock? Curr Opin Oncol. 2013 Jul;25(4):417-24.
  5. Auriemma WS, Berger AC, Bar-Ad V, Boland PM, Cohen SJ, Roche-Lima CM, Morris GJ. Locally advanced pancreatic cancer. Semin Oncol. 2012 Aug;39(4):e9-e22.
  6. White MR, Boland P, Tecle T, Gantz D, Sorenson G, Tornoe I, Holmskov U, McDonald B, Crouch EC, Hartshorn KL. Enhancement of antiviral activity of collectin trimers through cross-linking and mutagenesis of the carbohydrate recognition domain. J Innate Immun. 2010; 2(3):267-79.
  7. White MR, Doss M, Boland P, Tecle T, Hartshorn KL. Innate immunity of influenza virus: implications for future therapy. Exp Rev Clinical Immunol. July 1 2008; 4(4): 497-514.
  8. Boland PM, Dhillon RS, Goldstein SD, O'Hara BJ, Kastenberg DM. Adenocarcinoma of the prostate presenting as an obstructing rectal mass. Dig Dis Sci. Oct 2007; 52(10): 2800-5.

Abstracts:

  1. Vijayvergia N, Boland PM, Gustafson KS, Sheriff F, Cooper H, Cohen SJ, Astaturov I,  Engstrom PF. Molecular profiling of advanced stage Neuroendocrine Tumors (NETs): The Fox Chase Cancer Center (FCCC) experience. NANETS: 2014 Neuroendocrine Tumor Symposium, Accepted for presentation
  2. Hall MJ, Boland PM, Ruth K, Matro JM, Rainey K, Fang CY, Wong YN, Daly MB. Incorporating genomic testing using next-generation sequencing (NGS) into clinical practice: Genetic counselors’ (GC) experience, knowledge, and perceived competence.2014 ASCO Annual Meeting, Abstract #e17624. J Clin Oncol 32, 2014 (suppl; abstr e17624)
  3. Innocent J, Ruth K, Boland PM, Rainey K, Fang CY, Cohen SJ, Matro JM, Chertock Y, Wong YN, Daly MB, Hall MJ. Academic (AO) and community (CO) oncologists’ knowledge, understanding, and preparedness for clinical next-generation sequencing genomic testing (NGSGT).2014 ASCO Annual Meeting, Abstract #e17635. J Clin Oncol 32, 2014 (suppl; abstr e17635)
  4.  Boland PM, Skarbnik AP, Cristofanilli M, Alpaugh RK, Olszanski AJ. Application of next generation sequencing (NGS) for evaluation of advanced epithelial cancers: A single institution experience. 2013 ASCO Annual Meeting, Abstract #11092. J Clin Oncol 31, 2013 (suppl; abstr 11092).

Patrick McKay Boland

Assistant Professor

 

  • :(716) 845 - 3099
    Fax No.:(716) 845 - 8935

  • DEPARTMENTDepartment of Medicine
    Roswell Park Cancer Institute
  • COUNTRY USA